5 days SNY and REGN’s Dupixent sBLA for Skin Disease Gets FDA’s Priority Tag Zacks

   X     

3 weeks Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval Zacks

   X     

3 weeks Company News for Feb 5, 2025 Zacks

   X     

3 weeks Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend Zacks

   X     

3 weeks Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript Seeking Alpha

   X     

3 weeks Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics Zacks

   X     

3 weeks Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates Zacks

   X     

3 weeks Regeneron to Report Q4 Earnings: Is a Beat in the Cards? Zacks

   X     

3 weeks Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics Zacks

   X     

4 weeks Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline Zacks

   X     

1 month Regeneron Reports Eylea Sales, Provides Other Pipeline Updates Zacks

   X     

1 month Regeneron Pharmaceuticals, Inc. (REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript) Seeking Alpha

   X     

1 month Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold? Zacks

   X     

1 month Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again Zacks

   X     

2 months REGN’s Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study Zacks

   X     

2 months Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains Zacks

   X     

2 months Regeneron Down 15.5% Year to Date: How to Play the Stock? Zacks

   X     

3 months Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript) Seeking Alpha

   X     

3 months Do Options Traders Know Something About Regeneron (REGN) Stock We Don’t? Zacks

   X     

3 months Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript) Seeking Alpha

   X     

3 months FDA Accepts SNY and REGN’s Dupixent Re-Submitted sBLA for Urticaria Zacks

   X     

4 months Regeneron Pharma earnings beat by $0.74, revenue topped estimates Investing.com

   X     

4 months Regeneron to Report Q3 Earnings: What’s in the Offing? Zacks

   X     

4 months Brighton Jones LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) MarketBeat

   X     

4 months Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Silver Oak Securities Incorporated MarketBeat

   X     

4 months Regeneron Pharmaceuticals (NASDAQ:REGN) Receives “Neutral” Rating from Cantor Fitzgerald MarketBeat

   X     

4 months Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,080.00 at Barclays MarketBeat

   X     

4 months Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,050.00 by Analysts at Wells Fargo & Company MarketBeat

   X     

4 months Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Outperform” Rating from Royal Bank of Canada MarketBeat

   X     

4 months Creative Planning Purchases 2,178 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) MarketBeat

   X     

4 months Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Raymond James & Associates MarketBeat

   X